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Abstract
Background: Clinical trials remain key to the development of evidence-based medical
practice. However, they are becoming increasingly complex, mainly in a multinational
setting. To address these challenges, the European Union (EU) adopted the Clinical
Trial Regulation EU No. 536/2014 (CTR). Once in force, the CTR will lead to more
consistent rules and simplification of procedures for conducting clinical trials through-
out the EU. Existing harmonization initiatives and “research infrastructures” for clini-
cal trials may facilitate this process. This publication offers a snapshot of the current
level of harmonization activities in academic clinical research in Europe.
Methods: A survey was performed among the member and observer countries of the
European Clinical Research Infrastructure Network (ECRIN), using a standardized
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questionnaire. Three rounds of data collection were performed to maximize com-
pleteness and comparability of the received answers. The survey aimed to describe
the harmonization of academic clinical research processes at national level, to facili-
tate the exchange of expertise and experience among countries, and to identify new
fields of action.
Results: Most scientific partners already have in place various working groups and
harmonization activities at national level. Furthermore, they are involved in and open
to sharing their know-how and documents. Since harmonization was mainly a
bottom-up approach up until now, the extent and topics dealt with are diverse and
there is only little cross-networking and cross-country exchange so far.
Conclusions: Currently, the ECRIN member countries offer a very solid base and col-
laborative spirit for further aligning processes and exchanging best practices for clini-
cal research in Europe. They can support a smooth implementation of the EU CTR
and may act as single contact with consolidated expertise in a country.
K E YWORD S
clinical research, clinical study, clinical trial, ECRIN, EU 536/2014, harmonization of processes,
survey
1 | INTRODUCTION
Clinical trials remain key to the development of evidence-based medi-
cal practice. Over the years, there has been a growing trend to per-
form large-scale clinical trials across borders, not only in industry but
in academic settings as well. Multinational collaboration brings many
advantages for all types of clinical trials. Trial participant recruitment
is faster, and the results of the trial are more generally applicable. On
the other hand, multinational clinical trials are significantly more com-
plex to perform than national ones due in particular to the difficulties
arising from the diversity of legal frameworks and operational prac-
tices. This is particularly true for the conduct of multinational trials
initiated by academic institutions, which often do not have well-
developed on-site management support. As a consequence, only 3%
of academic trials are international (whereas 30% of industry trials are
international).1 In addition, the number of clinical trials, particularly
those initiated by academic investigators, has been falling in recent
years in many regions, including the European Union (EU).2
In order to improve this situation, the EU adopted the Clinical
Trial Regulation EU No. 536/2014 (CTR3). Once in force, the CTR will
lead to harmonized rules for conducting clinical trials throughout the
EU. This will increase the efficiency of all trials in Europe with the
greatest benefit for those conducted in multiple European Member
States. It aims, among other things, to improve collaboration,
information-sharing, and decision-making between and within Mem-
ber States.3 The Heads of Medicines Agencies (HMA) established the
Clinical Trials Facilitation Group (CTFG) in order to harmonize activi-
ties across Member States.4 To ease the implementation of the CTR,
pilot projects have begun at national level in some countries. These
national pilot projects have focused on coordinated assessment by
national competent authorities (NCAs) and ethics committees (ECs)
within a single Member State.4
To what extent does harmonization of clinical research already
exist in Europe? Through the Voluntary Harmonization Procedure
(VHP), which was implemented in 2009 by the HMA, preliminary
experience has been gained for the harmonization of clinical trial
applications in particular (through mutual assessments). The CTR will
further change and harmonize many processes related to multina-
tional clinical trials, and these processes need to be adopted by exis-
ting “research infrastructures” and institutions. The term “research
infrastructure” is used here to mean an organization that provides
facilities, resources, or related services to researchers to enable top-
level scientific research; in the particular context of this article, we
refer specifically to “infrastructures” that support multinational clinical
research in Europe. We believe that these types of infrastructures, as
well as existing harmonization processes (at national level), may be rel-
evant for the implementation of the CTR (and beyond). As such, this
paper aims to provide a snapshot of the current level of harmonization
activities in clinical research; it also provides an overview of the cur-
rent/potential role of infrastructures such as the European Clinical
Research Infrastructure Network (ECRIN) to align harmonization pro-
cesses between countries, in accordance with the expectations or
requirements of the CTR (see also Appendix S1 for major changes
under the CTR).
ECRIN is a public, nonprofit organization that links scientific part-
ners and networks across Europe in order to facilitate multinational
clinical research.5 Established in 2004, ECRIN was awarded the legal
status of a “European Research Infrastructure Consortium” (ERIC) in
2013. ECRIN's scientific partners are national networks that are com-
posed of academic clinical research centers (CRCs) or clinical trial units
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(CTUs) with a national coordinating center (Table 1). As per the
ECRIN-ERIC statutes, the scientific partners must have developed
shared tools, procedures, and practices to facilitate multicenter stud-
ies and have reached a “critical mass” in terms of competency.6
ECRIN's scientific partners are involved in various harmonization
activities at national level and beyond. To identify the scope of these
activities, a survey was performed in ECRIN member and observer
countries. The findings of the survey are also intended to support the
identification of new fields of action for ECRIN to increase the quality
and efficiency of multinational clinical research.
2 | RESEARCH INTERESTS
Research interests of the survey cover a status report on harmoniza-
tion activities and the identification of possibilities to improve.
• To identify the current level of harmonization activities in clinical
research prior to implementation of the EU CTR
• To enable synergies by facilitating the exchange of expertise and
experience in national harmonization in clinical research
• To identify new fields of action for ECRIN to increase the quality
and efficiency of multinational clinical research
3 | METHODS
A survey was performed among ECRIN's national scientific partners in
its member and observer countries (see Table 1) using a standardized,
open-ended questionnaire.
Background information about ECRIN is given in Appendix S2.
In Table 2, basic data about the National Clinical Research Net-
works belonging to ECRIN are summarized.
Three rounds of data collection were performed between April
2018 and January 2019 to maximize completeness and comparability
of the answers received. The detailed procedure of the data collection
rounds is already described by Magnin et al.7
The survey consisted of two parts, one dealing with national har-
monization activities and the other with national training activities.
The results of the latter were published in the Trials Journal.7 This
report summarizes the results of the survey describing the harmoniza-
tion of academic clinical research processes at national level. The
questionnaire is included in Appendix S3.
4 | RESULTS
All ECRIN member and observer countries participated in the survey.
Table 3 gives an overview of the responses on national harmonization
activities, as provided by ECRIN's different scientific partner
networks.
4.1 | Working groups
All but one of the scientific partners have established (or participate in
national) working groups (WGs) in order to harmonize practices. In
many cases, there is a systematic approach for collaboration.
Depending on the topic, collaboration may also be opportunity driven.
WGs (or initiatives) by country are as follows:
• Czech Republic: “Working Committee for Clinical Trials at the Min-
istry of Health”
• France: WG on harmonization of practices with French industry
• Germany: numerous WGs with all relevant stakeholders to imple-
ment common standards in relevant fields
• Hungary: Human Resource Development Operational Program
(HRDOP) and its subprojects8
• Ireland: participation in various WGs through Health Research
Board—Clinical Research Coordination Ireland (HRB-CRCI)
• Norway: Consults with the medicinal authorities once a year and
provides consulting services on most aspects of a clinical trial, pri-
marily good clinical practice (GCP), contractual work, budget, data
management, and monitoring
TABLE 1 National clinical research networks belonging to ECRIN
Country ECRIN Scientific Partner
Czech
Republic
CZECRIN—Czech Clinical Research Infrastructure
Network https://www.czecrin.cz/
France F-CRIN—French Clinical Research Infrastructure
Network
https://www.fcrin.org/
Germany KKSN—Netzwerk der Koordinierungszentren für
Klinische Studien
https://www.kks-netzwerk.de/
Hungary HECRIN—Hungarian Clinical Research Infrastructure
Network https://hecrin.pte.hu/
Ireland HRB CRCI—Health Research board, Clinical Research
Coordination Ireland https://www.hrb-crci.ie/
Italy ISS—Istituto Superiore di Sanita/ItaCRIN—Italian
Clinical Research Infrastructure Network https://
www.itacrin.it/
Norway NorCRIN—Norwegian Clinical Research Infrastructure
Networkhttps://www.norcrin.no/
Portugal PtCRIN—Portuguese Clinical Research Infrastructure
Network http://www.ptcrin.pt/
Slovakiaa SLOVACRIN—Slovak Clinical Research Infrastructure
Network https://slovacrin.sk/
Spain SCReN—Spanish Clinical Research Network https://
www.scren.es/en/scren.php
Switzerlanda SCTO—Swiss Clinical Trial Organization https://www.
scto.ch/en/news.html
Note. Link to short descriptions of the ECRIN scientific partners (members
and observers) listed above: https://www.ecrin.org/who-we-are/
members-observers
aObserver.
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• Portugal: WGs on trial participant reimbursement, implementation
of General Data Protection Regulation (GDPR), patient access to
trial information, human resource recruitment for CRCs, and trans-
lation of medical device standards
• Slovakia: initiative to establish a national contract template for clin-
ical trials and training program for CTU staff
• Spain: development and implementation of the new clinical trial
legislation
• Switzerland: 8 expert WGs (ie, thematic platforms) of the network
to streamline clinical research and active participation in
national WGs9
4.2 | Consulting
Consultation is provided in 10 countries and may be initiated by net-
works or asked for by national partners. In each country, this covers
the following:
• Czech Republic: consultation on specific study documents and
legal documents (eg, adoption of CT directive initiated by the
national regulatory agency SUKL)10
• France: consultation with external bodies (eg, Ministry of
Health [MOH])
• Germany: consultation on laws and regulations (eg, leading role in
radiation protection law, implementation of GDPR, national imple-
mentation on medical device regulation [MDR])
• Hungary: consultation is provided as part of the HRDOP8
• Ireland: consulting on any relevant issues
• Norway: consulting within the above-mentioned WGs
• Portugal, Spain, and Switzerland: consultation on laws and regula-
tions in collaboration with national bodies (eg, human research act,
biobank regulations, and type of intervention and submission
process)
• Slovakia: a national advisory group of all experts and stake-
holders in clinical research is planned
It should be stated here that consultancy may have been
interpreted differently between the national partners (see
Section 5).
4.3 | Standard operating procedures
Six countries are working on or have provided harmonized standard
operating procedures (SOPs) (for external and network internal use),
which have to be adapted to local processes (Czech Republic, Ger-
many, Norway, Spain). Portugal developed SOPs for monitoring for
newly established CTUs and disseminates SOPs developed by interna-
tional organizations; furthermore, their WGs will issue additional
SOPs. In Switzerland, SOPs are developed within the thematic plat-
forms; furthermore, an overarching Guideline for Good Operational
Practices is available for free.11T
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4.4 | Templates/tools
Templates and tools have been developed by seven scientific partners
(for network internal purposes and general use). This involves, for
example, templates for national grant proposals in Czech Republic
(network internal use); templates for GDPR-compliant patient sheets
in Germany; standard Clinical Trial Agreements (CTAs) and costing
templates in Ireland; several templates in Switzerland, e.g. a tool for
risk-adapted monitoring,12 data management guidelines, as well as
many templates in collaboration with swissethics.13
4.5 | Services
The Czech network is responsible for the national harmonization of
services (not further specified). The French network is involved in a
national “train the trainer” program for clinical research. In Germany,
the output from consulting and WGs sometimes results in services.
Ireland reported the provision of services covering streamlined feasi-
bility services, pharmacovigilance (PV) services, and management of a
central contact point for Ireland. Norway supports the pharmaceutical
industry and academic researchers by streamlining processes.14
4.6 | Other activities and general remarks
In Ireland, a mutual recognition scheme for quality management (QM) for
the HRB CRCI network and a clinical research program for the country
have been established. In Hungary, the HRDOP was created to develop
and internationalize a thematic network for clinical research, with the
involvement of HECRIN. In Portugal, a course for hospital managers on
CRC organization was offered in collaboration with the Portuguese Associa-
tion of Hospital Managers (APAH) and the Portuguese Association of the
Pharmaceutical Industry (APIFARMA). For Norway, see above (underWGs).
The mandate of the French network was initially more focused
on bringing different players together to improve efficiency (through
“structuring”). The better the collaboration between actors, the more
national harmonization can be seen. The KKS-Network in Germany is
contributing to a broad range of issues related to clinical research.
In Italy, the national context is going to change due to a new law
that will provide rules on several aspects of clinical research, including
educational programs for operators and requirements for the clinical
sites involved in phases I to IV clinical trials.15
As of December 2018, a new ERASMUS+ project (“Curriculum
Development of Human Clinical Trials for the Next Generation Bio-
medical Students,” CONSCIOUS) has been initiated. The project
leader is HECRIN, and the scientific partners are CZECRIN, PtCRIN,
F-CRIN, and MMI Clinical Research Development Ireland. The general
objective of the CONSCIOUS project is to tackle the skill gaps and
mismatches related to European-level clinical trial professionals
through curriculum development and preparation of e-learning mate-
rial for the career development of biomedical (medical, pharmacy, clin-
ical research master) students.
The current state of harmonization efforts in training and curric-
ula for clinical research is described in Magnin et al.7
4.7 | Sharing templates/documents/
recommendations
All countries share templates/documents/recommendations devel-
oped in their network, except for Italy, which shares only within
ECRIN-related studies. In addition, some countries provide external
access upon request (Portugal), or on a cases-by-case basis (Germany),
or for specific documents (Switzerland). Open and free access is pro-
vided by Ireland (with a disclaimer), and this will be the case for Nor-
way, Slovakia, and Switzerland in the future.
Appendix S4 provides a noncomprehensive overview with useful
links provided by the scientific partners. Furthermore, ECRIN harmo-
nization activities and corresponding links are listed as well. To estab-
lish a more comprehensive future repository as planned by ECRIN,
more conceptual work and resources are required, including a process
to maintain the information (see also Section 5).
4.8 | Local/national certification programs for
clinical research
The majority of countries offer no local/national certification pro-
grams for aspects of clinical research (Czech Republic, Germany, Hun-
gary, Norway, Switzerland). In France, researchers who attended a
6-day training course for educational development of clinical investi-
gation trainers received a certificate. In Italy, certification is necessary
for phase 1 units, in Spain, the latter certification is available, but not
mandatory, and in Portugal, investigators and research teams are cer-
tified in GCP. In Ireland, HRB-CRCI has established a mutual recogni-
tion scheme for QMS, issuing a letter. In addition, there is a graduate
certificate in clinical research from the University College Dublin
(UCD). In Germany and Switzerland, audits (but not certification) are a
prerequisite for membership. The answers are summarized in Table 4.
It should be noted that there is some diversity of interpretation and
use of terms related to certification (see Section 5).
4.9 | Influence on national harmonization
regarding clinical research
A broad spectrum of ratings of the influence of ECRIN scientific part-
ners on harmonization of clinical research in their country was
observed. The influence was rated as “high” in three countries, “mod-
erate” in two countries, “low” in three countries, and “very low” in one
country. One country reported “low” in harmonization but “very high”
in structuring and one “moderate to high.” One country that rated the
influence as “low” stated that more governmental support is needed
for the implementation of harmonization. Another rating was “moder-
ate” because the network is only 3 years in operation; however, it is
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TABLE 3 Summary of answers to the question: “To what extent do you work on the harmonization of clinical research processes at national
level?”
Harmonization activity
Country
CZE FRA DEU HUN IRL ITAa NOR POR SVK ESP CHE
Working groups X X X X X X X X X X
Consulting X X X X X X X X X X
SOPs X X X X X X
Templates, tools X X X X X X X
Services X X X X X
Curricula for CR staff X X (X) X X
Other activities X X X X X
Abbreviations: CZE Czech Republic, FRA France, DEU Germany, HUN Hungary, IRE Ireland, ITA Italy, NOR Norway, POR Portugal, SVK Slovakia, ESP
Spain, CHE Switzerland; SOPs, standard operating procedures; CR, clinical research; X, available; (X), planned.
aIn construction phase.
TABLE 4 Answers to the question “Do you have or offer local/national certification programs for aspects of clinical research?”
Country Do you have or offer local/national certification programs for aspects of clinical research?
Czech
Republic
No, but currently discussing within the “Working Committee for Clinical Trials at the Ministry of Health” (planned start date: May 2019)
France Sites performing phase I/first-in-man trials need certification.
Evaluation of disease-targeted investigator networks undergoing a specific selection program results in labelling, not certification.
Certification of trainers attending the training course for educational development of clinical investigation trainers.16
Germany Audits for new KKS members are a prerequisite for membership. Also teaching curricula certification. Target group: within network.
Hungary No. The National Institute of Pharmacy and Nutrition (OGYÉI) is the authority: they offer and perform the local certification program.
Consortium members organize professional conferences, where it is possible to complete the GCP course for all interested (external
and internal) parties.
As the part of the HRDOP project (Education development subproject) we are also working on curriculum development. The teaching
materials developed for clinical trial staff (study coordinator, study nurse, investigator, sub-investigator) will be available not only
within the universities but also externally.
Ireland Yes, on completion of the Mutual Recognition Scheme for QMS, the centers are issued a letter of completion (mutual recognition) from
HRB-CRCI.
ICH GCP training for Investigational Medicinal Products (IMPs) and medical devices is carried out by the Clinical Research Facilities and
Centers (CRF/C's) in the network and certificates of completion are issued by the centers.
The target groups for these courses are the CRF/C's and their staff as well as the investigator teams running the trials from the
hospitals engaged with the CRF/C's for clinical research.
Individual centers offer a range of different clinical research training courses in addition to those listed above.
Italy Certification is required for clinical research organizations (CROs) (for any kind of study) and for clinical sites only if involved in phase I
studies. In both cases they self-certify their activities. Inspections by the Italian Competent Authority will follow. We do not offer any
certification programs.
Norway Planned: certification program for study nurses/coordinators.
In discussion: certification “light” for early phase units.
Portugal Clinical Investigator Certificate17 is an e-learning-based course of 16h (Level I) and 40h (Level II) training. The program is based on the
syllabus published by PharmaTrain and ECRIN (Boeynaems et al18). A GCP certificate is obtained by clinical research staff and
investigators after passing the final exam. One CTU is certified under ISO 9001:2015 rules that also certifies recruitment centers in
ophthalmology (national and international)
Slovakiaa No
Spain Some CTUs are:
• Certified under ISO 9001:2015 rules
• Certified for GCP compliance (Phase I units)
Switzerlanda No certification programs for CTUs and research institutes (however, audits are a prerequisite for new members).
Trainings and certificates for clinical research professionals.
aObserver.
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already collaborating with the major stakeholders. In the country with
a rating of “moderate to high,” the national network has become a rec-
ognized stakeholder for academic research; however, so far, there
was little involvement in the legislative process.
4.10 | Perception as facilitator for clinical research
All of ECRIN's scientific partners are perceived as facilitators rather
than an additional source of bureaucracy. Three countries added that
CTUs might be perceived as increasing administrative workload, since
they continue to ask researchers to comply with the regulations (for
the sake of quality but resulting in more paperwork).
5 | DISCUSSION
Almost all ECRIN members are involved in national harmonization
activities and are open to sharing their know-how and documents.
However, since harmonization was mainly a bottom-up approach up
until now, the extent and topics dealt with are diverse and there is lit-
tle cross-network exchange so far.
Currently, ECRIN member and observer countries offer a very
good foundation and collaborative spirit to further align processes and
exchange best practices for clinical research in Europe. This will play a
key role not only for competitiveness in clinical research but also for
building transnational awareness. Even though there is little system-
atic approach for (top-down) strategic and overarching considerations,
the already existing network will facilitate a stronger, future, EU
cross-border exchange. ECRIN members and observers can support a
smooth implementation of the EU CTR and may act as a single contact
with consolidated expertise in a country (see Appendix S2). By further
coordinating its members/observers, and with the CTR providing a
general framework, ECRIN will be able to further promote harmoniza-
tion activities across Europe. This is contingent, however, on sustain-
able funding for ECRIN's national scientific partners. Governments
should be aware of the critical need for funding for this type of activ-
ity as well as its excellent potential return on investment.
Furthermore, as a clinical research infrastructure, ECRIN's (and its
scientific partners') services are not limited to clinical trials but offered
for any kind of clinical research (this may, as an example, include non-
interventional clinical research, reuse of biosamples, and patient data).
The potential for multinational harmonization through clinical research
infrastructures may even be higher in those areas of clinical research
that are not regulated under the CTR.
5.1 | Use of the survey results as an inventory to
exchange experience and expertise:
A significant amount of experience and expertise is available within
the ECRIN member and observer countries, yet knowledge exchange
could be improved. Systematic exchange between countries may
challenge and enrich national views and provide exposure to the
broader European picture and vice versa. Lastly, the access to infor-
mation, documents, and expertise should lead to a mutual benefit for
all members, avoiding duplication of efforts and a waste of taxpayer
money. Examples for such an exchange of expertise are how to handle
GDPR, general consent processes, big data and data governance at
institutional level, impact of personalized health on clinical research,
and “horizon scanning” at European level. Furthermore, the interac-
tion between ECRIN partners may facilitate the understanding of spe-
cific clinical trial–related regulatory processes, which, according to
regulation 536/2014, have to be implemented at the national level by
Member States. ECRIN and its scientific partners may also be an indis-
pensable partner for the EU (respectively the responsible taskforces)
in continuously harmonizing and implementing processes at European
level once the CTR comes into force.
5.2 | Further new fields of action for ECRIN to
increase the quality and efficiency of multinational
clinical research
• Certification: As a first successful model, ECRIN has implemented
the certification of data centers.19 As a next step, certification in
other areas could be envisaged (eg, pharmacovigilance or phase
1 units) to facilitate collaboration between partners in a multina-
tional clinical trial.
• Closer collaboration with other “research infrastructures” could be
an aim for the certification of biobanks, for example.
• Collaboration with different international registries for clinical trials
in order to align content and improve comparability (eg, to better
identify funding sources and data ownership).20
• Transnational implementation of the Erasmus+ CONSCIOUS pro-
ject on innovative educational methodology will provide a new tool
for many countries to standardize clinical trials and increase their
efficiency at EU level and worldwide.
• ECRIN national scientific partners need to work towards more visi-
bility at national level to foster quality and efficiency of multina-
tional clinical research.21
• Collaboration and agreements to facilitate cross-border data shar-
ing through harmonized processes and best practices (citation:
“The more broadly adopted standards (for data, metadata, models,
and terminology), the easier the sharing of data and communica-
tion of meaning along with that data”).22
• A similar survey performed on a regular basis will make it possible
to evaluate the “structuring effect” of ECRIN over time.
5.3 | Limitations of the survey
Data collection was limited to 11 ECRIN member and observer coun-
tries through the coordinating units of the national scientific partners.
The ECRIN partners served as a convenient and representative sam-
ple. However, we cannot exclude other harmonization activities not
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known to the networks. In addition, the national networks of the
member/observer countries are all organized differently, ranging from
few units providing services nationwide to a network of up to 30 CTUs
across the country.23 As a consequence, the information is very het-
erogeneous and may not be complete in all cases and thus may not be
representative for the entire EU.
In addition, diversity of interpretation and use of terms was iden-
tified in the survey as, for example, the “process of certification.” Does
it mean a very rigorous process like ISO certification or does it refer
to the simpler process of getting, for example, a certificate for train-
ing? Also “consultancy” was interpreted differently: consultancy as a
core business of CTUs for researchers vs acting as experts for differ-
ent bodies and authorities. For future surveys, such expressions
should be better defined or provided in closed-ended questions.
Nevertheless, the survey has been performed in three rounds
with stepwise improvement of the information and face-to-face dis-
cussions between the survey participants and thus gives a good over-
view on harmonization activities in the participating countries. Just
recently, Poland joined ECRIN as an observer, and hence, future
updates will be even more comprehensive.
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